Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.75
USD
|
+4.79%
|
|
-8.85%
|
-87.13%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
244.9
|
67.68
|
34.15
|
12.6
|
-
|
-
|
Enterprise Value (EV)
1 |
244.9
|
67.68
|
34.15
|
12.6
|
12.6
|
12.6
|
P/E ratio
|
-13.4
x
|
-3.58
x
|
-1.33
x
|
-0.25
x
|
-0.52
x
|
-0.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
188
x
|
55.4
x
|
48.2
x
|
-
|
189
x
|
-
|
EV / Revenue
|
188
x
|
55.4
x
|
48.2
x
|
-
|
189
x
|
-
|
EV / EBITDA
|
-14,804,685
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-1.77
x
|
-0.57
x
|
-0.79
x
|
-1.05
x
|
FCF Yield
|
-
|
-
|
-56.5%
|
-175%
|
-127%
|
-95.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,029
|
2,102
|
2,511
|
7,198
|
-
|
-
|
Reference price
2 |
120.7
|
32.20
|
13.60
|
1.750
|
1.750
|
1.750
|
Announcement Date
|
3/11/22
|
3/10/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.63
|
1.306
|
1.222
|
0.709
|
-
|
0.0667
|
-
|
EBITDA
|
-
|
-16.54
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-17.46
|
-18.04
|
-21.03
|
-22.31
|
-19.63
|
-22.21
|
Operating Margin
|
-
|
-1,336.6%
|
-1,476.51%
|
-2,966.01%
|
-
|
-29,447.02%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-18.84
|
-21.41
|
-22.31
|
-25.35
|
-32.42
|
Net income
1 |
-3.721
|
-17.05
|
-18.84
|
-21.41
|
-22.31
|
-21.45
|
-32.42
|
Net margin
|
-66.09%
|
-1,305.21%
|
-1,541.33%
|
-3,020.17%
|
-
|
-32,171.14%
|
-
|
EPS
2 |
-
|
-9.000
|
-9.000
|
-10.20
|
-7.000
|
-3.390
|
-2.600
|
Free Cash Flow
1 |
-
|
-
|
-
|
-19.3
|
-22
|
-16
|
-12
|
FCF margin
|
-
|
-
|
-
|
-2,722.57%
|
-
|
-23,998.8%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/21
|
3/11/22
|
3/10/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.209
|
0.37
|
0.466
|
0.265
|
0.121
|
0.279
|
0.217
|
0.15
|
0.063
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-3.8
|
-3.206
|
-3.297
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.032
|
-3.394
|
-4.221
|
-5.187
|
-5.239
|
-4.716
|
-5.712
|
-5.161
|
-5.44
|
-5.227
|
-4.995
|
-4.432
|
-4.049
|
-
|
Operating Margin
|
-1,929.19%
|
-917.3%
|
-905.79%
|
-1,957.36%
|
-4,329.75%
|
-1,690.32%
|
-2,632.26%
|
-3,440.67%
|
-8,634.92%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-5.624
|
-5.244
|
-4.456
|
-4.647
|
-5.632
|
-5.106
|
-6.028
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-4.069
|
-3.51
|
-5.624
|
-5.244
|
-4.456
|
-4.647
|
-5.632
|
-5.904
|
-6.028
|
-5.227
|
-4.995
|
-4.432
|
-4.049
|
-
|
Net margin
|
-1,946.89%
|
-948.65%
|
-1,206.87%
|
-1,978.87%
|
-3,682.64%
|
-1,665.59%
|
-2,595.39%
|
-3,936%
|
-9,568.25%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.000
|
-1.700
|
-2.700
|
-2.500
|
-2.100
|
-2.200
|
-2.700
|
-2.800
|
-2.500
|
-2.700
|
-2.700
|
-2.500
|
-2.300
|
-1.040
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/22
|
5/13/22
|
8/12/22
|
11/14/22
|
3/10/23
|
5/12/23
|
8/11/23
|
11/9/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-19.3
|
-22
|
-16
|
-12
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
0.3
|
0.2
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
42.45%
|
-
|
-
|
-
|
Announcement Date
|
3/30/21
|
3/11/22
|
3/10/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
1.75
USD Average target price
30.05
USD Spread / Average Target +1,617.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -87.13% | 12.6M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|